DGAP-News: MeVis Medical Solutions AG: MeVis publishes figures for the second quarter of fiscal year 2017/2018

Decline in sales in the second quarter as expected

• Revenues at EUR 4.4 million approximately 6 % below previous year's level
• EBIT of EUR 3.1 million in the first half year (compared to EUR 3.6 million in the previous year)
• EBIT margin stable at 38 % (previous year 37 %)
• Profit after tax of EUR 2.4 million (compared to EUR 3.6 million in the previous year)

Bremen, May 15, 2018 - MeVis Medical Solutions AG [ISIN: DE000A0LBFE4], a leading provider of medical imaging software, announces the results for the first half of fiscal year 2017/2018 (reporting period October 1, 2017 to March 31, 2018).

Sales in the second quarter of fiscal year 2017/2018 came to EUR 3,950 k, about 6 % below previous year (EUR 4,219 k). Licensing business declined by 10 % in the second quarter to EUR 1,438 k and maintenance business fell by 5 % to EUR 1,712 k. The service business slightly decreased from EUR 825 k in the previous year period to EUR 799 k. Revenues thus amounted to EUR 8,233 k in the first half of the year (prev. year: EUR 9,756 k), of which EUR 5,710 k was attributable to the Digital Mammography segment (prev. year: EUR 5,971 k) and EUR 2,523 k to Other Diagnostics (prev. year: EUR 3,785 k). In the previous year, the revenues in the Other Diagnostics segment also included the one-off revenues of EUR 1,800 k from the sale of MeVisLab usage rights. At 69 % (prev. year: 75 %, without one-off revenue from sale of usage rights), the Digital Mammography segment continues to be the main source of revenues at the Company.

Thus, the EBIT (earnings before financial result and taxes) of EUR 1,182 k was generated in the second quarter and EUR 3,136 k in the first half of the year, compared to EUR 735 k in the second quarter and EUR 3,610 k in the first half of the previous year. The EBIT margin increased slightly to 38 % compared to a previous year value of 37 %.

The financial result declined significantly in the period under review to EUR -768 k (prev. year:
EUR 1,095 k). In comparison to the previous year, there were significant changes in the balance of income and expenses from exchange rate differences of EUR -1,280 k (prev. year: EUR 1,180 k), as well as in the earnings of the 51 % share in MeVis BreastCare GmbH & Co. KG of EUR 444 k (prev. year: EUR -135 k), which is recognized at equity.

Earnings after taxes amounted to EUR 2,366 k (prev. year: EUR 3,555 k), which corresponds to undiluted earnings per share of EUR 1.30 (prev. year: EUR 1.95).

The interim report for the third quarter of fiscal year 2017/2018 will be published on August 21, 2018.